BCAL Diagnostics Limited's (ASX:BDX) Profit Outlook

We feel now is a pretty good time to analyse BCAL Diagnostics Limited's (ASX:BDX) business as it appears the company may be on the cusp of a considerable accomplishment. BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. The AU$45m market-cap company announced a latest loss of AU$6.4m on 30 June 2024 for its most recent financial year result. Many investors are wondering about the rate at which BCAL Diagnostics will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

See our latest analysis for BCAL Diagnostics

Expectations from some of the Australian Biotechs analysts is that BCAL Diagnostics is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of AU$3.8m in 2026. So, the company is predicted to breakeven approximately 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 91%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

earnings-per-share-growth

Underlying developments driving BCAL Diagnostics' growth isn’t the focus of this broad overview, however, bear in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 7.5% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of BCAL Diagnostics to cover in one brief article, but the key fundamentals for the company can all be found in one place – BCAL Diagnostics' company page on Simply Wall St. We've also compiled a list of important aspects you should further research:

1. Valuation: What is BCAL Diagnostics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether BCAL Diagnostics is currently mispriced by the market.

2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on BCAL Diagnostics’s board and the CEO’s background.

3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.